(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are FIRST REPUBLIC BANK, Cardlytics, and Cidara Therapeutics.

The three biggest losers today are Check-Cap Ltd., Check-Cap Ltd., and Artelo Biosciences.

Winners today

1. FIRST REPUBLIC BANK (FRC) – 34.24%

First Republic Bank, together with its subsidiaries, provides private banking, private business banking, and private wealth management services to clients in metropolitan areas in the United States. It operates in two segments, Commercial Banking and Wealth Management. The company accepts deposit products, such as noninterest-bearing checking, interest-bearing checking, money market checking accounts, money market savings accounts, and passbook accounts, as well as certificates of deposit. It also offers a range of lending products that comprise residential mortgage loans, home equity lines of credit, multifamily loans, commercial real estate and construction loans, personal and business loans, single family construction loans, and other loans and lines of credit to businesses and individuals. The company's loans are secured by single family residences, multifamily buildings, and commercial real estate properties. In addition, it provides wealth management services, which include various investment strategies and products, online investment management, trust and custody, full service and online brokerage, financial and estate planning, and access to alternative investments, as well as investing, insurance, and foreign exchange services. Further, the company offers online and mobile banking services; refinancing services; and ATM and debit cards. As of December 31, 2021, it offered its services through 82 licensed deposit taking offices primarily in the San Francisco, Palo Alto, Los Angeles, Santa Barbara, Newport Beach and San Diego, California; Portland, Oregon; Boston, Massachusetts; Palm Beach, Florida; Greenwich, Connecticut; New York, New York; and Jackson, Wyoming. It also has 12 additional offices that offer lending, wealth management, or trust services. First Republic Bank was founded in 1985 and is headquartered in San Francisco, California.

NYSE ended the session with FIRST REPUBLIC BANK jumping 34.24% to $16.35 on Tuesday, after four successive sessions in a row of losses. NYSE rose 1.41% to $14,985.95, following the last session’s upward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, FIRST REPUBLIC BANK has a trailing twelve months EPS of $6.4.

PE Ratio

FIRST REPUBLIC BANK has a trailing twelve months price to earnings ratio of 2.55. Meaning, the purchaser of the share is investing $2.55 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.99%.

Volatility

FIRST REPUBLIC BANK’s last week, last month’s, and last quarter’s current intraday variation average was a negative 38.00%, a negative 5.19%, and a positive 3.68%.

FIRST REPUBLIC BANK’s highest amplitude of average volatility was 38.00% (last week), 9.34% (last month), and 3.68% (last quarter).

Moving Average

FIRST REPUBLIC BANK’s value is way under its 50-day moving average of $128.47 and way below its 200-day moving average of $136.93.

More news about FIRST REPUBLIC BANK.

2. Cardlytics (CDLX) – 23.83%

Cardlytics, Inc. operates an advertising platform within financial institutions digital channels that include online, mobile, email, and various real-time notifications in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.

NASDAQ ended the session with Cardlytics jumping 23.83% to $3.69 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Cardlytics has a trailing twelve months EPS of $-13.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.13%.

Moving Average

Cardlytics’s worth is way below its 50-day moving average of $5.64 and way under its 200-day moving average of $10.55.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 76.3% and positive 15.4% for the next.

More news about Cardlytics.

3. Cidara Therapeutics (CDTX) – 16.95%

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Cidara Therapeutics jumping 16.95% to $2.07 on Tuesday while NASDAQ jumped 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Cidara Therapeutics has a trailing twelve months EPS of $-1.802.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -840.18%.

Moving Average

Cidara Therapeutics’s worth is way above its 50-day moving average of $1.45 and way higher than its 200-day moving average of $0.83.

Revenue Growth

Year-on-year quarterly revenue growth grew by 475.8%, now sitting on 61.29M for the twelve trailing months.

More news about Cidara Therapeutics.

4. FuboTV (FUBO) – 15.45%

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

NYSE ended the session with FuboTV rising 15.45% to $1.27 on Tuesday while NYSE rose 1.41% to $14,985.95.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-3.735.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.5%.

Sales Growth

FuboTV’s sales growth is 23.6% for the present quarter and 25.7% for the next.

Volume

Today’s last reported volume for FuboTV is 15842600 which is 29.01% above its average volume of 12279200.

More news about FuboTV.

5. Bellerophon Therapeutics (BLPH) – 13.91%

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

NASDAQ ended the session with Bellerophon Therapeutics rising 13.91% to $7.37 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Bellerophon Therapeutics has a trailing twelve months EPS of $-3.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -114.92%.

Volume

Today’s last reported volume for Bellerophon Therapeutics is 1653080 which is 29.21% below its average volume of 2335430.

More news about Bellerophon Therapeutics.

6. Cemtrex (CETX) – 13.48%

Cemtrex, Inc. operates as a technology company in the United States and internationally. The company operates through two segments, Advanced Technologies and Industrial Services. The Advanced Technologies segment provides Internet of Things products and smart devices under the SmartDesk name for mobile, web, virtual and augmented reality, wearables, and television markets; and security and video surveillance solutions, and virtual and augmented reality solutions for various commercial and industrial applications. This segment also offers browser-based video monitoring systems and analytics-based recognition systems, cameras, servers, and access control systems for security and surveillance in industrial and commercial facilities, federal prisons, hospitals, universities, schools, and federal and state government offices. The Industrial Services segment offers single-source services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly; installs high precision equipment in various industrial markets comprising automotive, printing and graphics, industrial automation, packaging, chemicals and others; and provides maintenance and contracting solutions for the machinery, packaging, printing, chemical, and other manufacturing markets. The company was formerly known as Diversified American Holding, Inc. and changed its name to Cemtrex, Inc. in December 2004. Cemtrex, Inc. was incorporated in 1998 and is based in Brooklyn, New York.

NASDAQ ended the session with Cemtrex rising 13.48% to $8.97 on Tuesday while NASDAQ jumped 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Cemtrex has a trailing twelve months EPS of $-1.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.61%.

More news about Cemtrex.

7. Marathon (MARA) – 13.1%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets in United States. As of December 31, 2021, it had approximately 8,115 bitcoins, which included the 4,794 bitcoins held in the investment fund. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Marathon rising 13.1% to $8.88 on Tuesday, following the last session’s downward trend. NASDAQ jumped 1.58% to $11,860.11, following the last session’s upward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-0.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.77%.

Yearly Top and Bottom Value

Marathon’s stock is valued at $8.88 at 17:32 EST, way below its 52-week high of $32.74 and way above its 52-week low of $3.11.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 270% and positive 53.8% for the next.

More news about Marathon.

8. UBS Group (UBS) – 12.47%

UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through four divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, and Investment Bank. The Global Wealth Management division offers investment advice and solutions, and lending solutions to ultra high net worth and high net worth clients. This segment also provides estate and wealth planning, investing, philanthropy, corporate and banking, and family advisory services, as well as mortgage, securities-based, and structured lending solutions. The Personal & Corporate Banking division provides personal banking products and services, such as deposits, cards, and online and mobile banking, as well as lending, investments, and retirement services; and corporate and institutional solutions, including equity and debt capital markets, syndicated and structured credit, private placements, leasing, traditional financing, trade and export finance, and global custody solutions, as well as transaction banking solutions for payment and cash management. The Asset Management division offers equities, fixed income, hedge funds, real estate and private markets, indexed and alternative beta strategies, asset allocation and currency investment strategies, customized multi-asset solutions, advisory and fiduciary services, and multi-manager hedge fund solutions and advisory services. The Investment Bank division advises clients on strategic business opportunities and helps them raise capital to fund their activities; enables its clients to buy, sell, and finance securities on capital markets and to manage their risks and liquidity; and offers clients differentiated content on major financial markets and securities. The company was formerly known as UBS AG and changed its name to UBS Group AG in December 2014. UBS Group AG was founded in 1862 and is based in Zurich, Switzerland.

NYSE ended the session with UBS Group jumping 12.47% to $21.15 on Tuesday while NYSE rose 1.41% to $14,985.95.

Earnings Per Share

As for profitability, UBS Group has a trailing twelve months EPS of $1.83.

PE Ratio

UBS Group has a trailing twelve months price to earnings ratio of 11.54. Meaning, the purchaser of the share is investing $11.54 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.96%.

Volume

Today’s last reported volume for UBS Group is 17851200 which is 444.23% above its average volume of 3280030.

Yearly Top and Bottom Value

UBS Group’s stock is valued at $21.15 at 17:32 EST, below its 52-week high of $22.30 and way higher than its 52-week low of $13.80.

Moving Average

UBS Group’s value is higher than its 50-day moving average of $21.10 and way above its 200-day moving average of $17.73.

More news about UBS Group.

9. Coinbase (COIN) – 11.94%

Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. The company offers the primary financial account in the cryptoeconomy for retailers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable ecosystem partners to build crypto-based applications and securely accept crypto assets as payment. Coinbase Global, Inc. was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase rising 11.94% to $84.11 on Tuesday while NASDAQ jumped 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $13.29.

PE Ratio

Coinbase has a trailing twelve months price to earnings ratio of 6.33. Meaning, the purchaser of the share is investing $6.33 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.35%.

More news about Coinbase.

10. Super Micro Computer (SMCI) – 9.93%

Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high-performance server and storage solutions based on modular and open architecture. Its solutions range from complete server, storage, modular blade servers, blades, workstations, full racks, networking devices, server management software, and server sub-systems, as well as security software. The company also provides application-optimized server solutions, including rackmount and blade servers, storage systems, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, SuperCloud Composer, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. It sells its products through direct and indirect sales force, distributors, value-added resellers, system integrators, and original equipment manufacturers. The company primarily operates in the United States, Europe, Asia, and internationally. Super Micro Computer, Inc. was incorporated in 1993 and is headquartered in San Jose, California.

NASDAQ ended the session with Super Micro Computer rising 9.93% to $108.30 on Tuesday while NASDAQ jumped 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Super Micro Computer has a trailing twelve months EPS of $1.64.

PE Ratio

Super Micro Computer has a trailing twelve months price to earnings ratio of 66.16. Meaning, the purchaser of the share is investing $66.16 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.49%.

Volatility

Super Micro Computer’s last week, last month’s, and last quarter’s current intraday variation average was 1.64%, 0.84%, and 3.25%.

Super Micro Computer’s highest amplitude of average volatility was 2.93% (last week), 3.53% (last month), and 3.25% (last quarter).

Moving Average

Super Micro Computer’s value is way higher than its 50-day moving average of $87.08 and way higher than its 200-day moving average of $69.77.

More news about Super Micro Computer.

Losers Today

1. Check-Cap Ltd. (CHEKZ) – -44.51%

NASDAQ ended the session with Check-Cap Ltd. falling 44.51% to $0.01 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Yearly Top and Bottom Value

Check-Cap Ltd.’s stock is valued at $0.01 at 17:32 EST, under its 52-week high of $0.01 and way above its 52-week low of $0.00.

More news about Check-Cap Ltd..

2. Check-Cap Ltd. (CHEK) – -42.24%

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis and report generation. The company was founded in 2004 and is based in Isfiya, Israel.

NASDAQ ended the session with Check-Cap Ltd. dropping 42.24% to $1.75 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Check-Cap Ltd. has a trailing twelve months EPS of $-4.04.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.39%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 18.3% and 14.2%, respectively.

Volume

Today’s last reported volume for Check-Cap Ltd. is 543058 which is 1005.12% above its average volume of 49140.

Moving Average

Check-Cap Ltd.’s value is way under its 50-day moving average of $3.30 and way under its 200-day moving average of $4.98.

More news about Check-Cap Ltd..

3. Artelo Biosciences (ARTLW) – -36.37%

NASDAQ ended the session with Artelo Biosciences sliding 36.37% to $0.06 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ jumped 1.58% to $11,860.11, following the last session’s upward trend on what was an all-around bullish trend exchanging session today.

Yearly Top and Bottom Value

Artelo Biosciences’s stock is valued at $0.06 at 17:32 EST, way under its 52-week high of $0.10 and way above its 52-week low of $0.04.

More news about Artelo Biosciences.

4. Brilliant Acquisition Corporation (BRLIW) – -32.43%

NASDAQ ended the session with Brilliant Acquisition Corporation sliding 32.43% to $0.02 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Yearly Top and Bottom Value

Brilliant Acquisition Corporation’s stock is valued at $0.02 at 17:32 EST, way below its 52-week low of $0.03.

More news about Brilliant Acquisition Corporation.

5. Athenex (ATNX) – -28.41%

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oral Docetaxel and Encequidar, a potent anticancer drug, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oral Topotecan and Encequidar, a potent anticancer drug that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and Oral Eribulin and Encequidar, an anticancer intravenous drug to treat certain patients with breast cancer and liposarcoma. In addition, the company offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis; Tirbanibulin Oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and PT01 (Pegtomarginase), an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

NASDAQ ended the session with Athenex falling 28.41% to $1.26 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Athenex has a trailing twelve months EPS of $-1.718.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -250.92%.

Sales Growth

Athenex’s sales growth for the current quarter is 19%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 90.5% and 43.8%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 123.09M for the twelve trailing months.

Moving Average

Athenex’s value is way under its 50-day moving average of $3.24 and way under its 200-day moving average of $6.34.

More news about Athenex.

6. First Majestic Silver (AG) – -22.38%

First Majestic Silver Corp. engages in the acquisition, exploration, development, and production of mineral properties with a focus on silver and gold production in North America. It holds 100% interests in the San Dimas Silver/Gold Mine covering an area of 71,868 hectares located in Durango and Sinaloa states; the Santa Elena Silver/Gold Mine covering an area of 102,244 hectares located in Sonora; Jerritt Canyon gold mine that covers an area of approximately of 30,821 hectares located in Elko County, Nevada; and the La Encantada Silver Mine covering an area of 4,076 hectares situated in Coahuila, as well as surface land ownership of 1,343 hectares. The company also holds 100% interests in the La Parrilla Silver Mine that covers an area of 69,478 hectares located in Durango; the Del Toro Silver Mine consisting of 3,815 hectares of mining concessions and 219 hectares of surface rights located in Zacatecas; the San Martin Silver Mine includes 33 mining concessions covering an area of 12,795 hectares located in Jalisco; and the La Guitarra Silver Mine that covers an area of 39,714 hectares located in Mexico. In addition, it holds interest in the Springpole project, a gold and silver project covering an area of approximately 41,913 hectares in Ontario, Canada. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006. First Majestic Silver Corp. was incorporated in 1979 and is headquartered in Vancouver, Canada.

NYSE ended the session with First Majestic Silver sliding 22.38% to $5.78 on Tuesday, after two sequential sessions in a row of gains. NYSE jumped 1.41% to $14,985.95, following the last session’s upward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, First Majestic Silver has a trailing twelve months EPS of $0.11.

PE Ratio

First Majestic Silver has a trailing twelve months price to earnings ratio of 53.47. Meaning, the purchaser of the share is investing $53.47 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.41%.

Moving Average

First Majestic Silver’s worth is way below its 50-day moving average of $7.44 and way below its 200-day moving average of $7.94.

More news about First Majestic Silver.

7. Viking Therapeutics (VKTX) – -19.73%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics dropping 19.73% to $9.34 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.67%.

More news about Viking Therapeutics.

8. ATIF Holdings Limited (ATIF) – -14.75%

ATIF Holdings Limited, a consulting company, provides financial consulting services to small and medium-sized enterprises in Asia. It primarily helps clients going public on the OTC markets and exchanges in the United States. The company was incorporated in 2015 and is headquartered in Rancho Cucamonga, California.

NASDAQ ended the session with ATIF Holdings Limited dropping 14.75% to $1.85 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Earnings Per Share

As for profitability, ATIF Holdings Limited has a trailing twelve months EPS of $-0.2.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.7%.

Yearly Top and Bottom Value

ATIF Holdings Limited’s stock is valued at $1.85 at 17:32 EST, way below its 52-week high of $4.03 and way above its 52-week low of $1.23.

Moving Average

ATIF Holdings Limited’s worth is way under its 50-day moving average of $2.48 and below its 200-day moving average of $1.95.

Volume

Today’s last reported volume for ATIF Holdings Limited is 3412 which is 45.97% below its average volume of 6316.

More news about ATIF Holdings Limited.

9. Apyx Medical Corporation (APYX) – -13.75%

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

NASDAQ ended the session with Apyx Medical Corporation dropping 13.75% to $2.51 on Tuesday, following the last session’s downward trend. NASDAQ jumped 1.58% to $11,860.11, following the last session’s upward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Apyx Medical Corporation has a trailing twelve months EPS of $-0.348.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.69%.

Volume

Today’s last reported volume for Apyx Medical Corporation is 61464 which is 73.07% below its average volume of 228255.

More news about Apyx Medical Corporation.

10. Boxlight Corporation (BOXL) – -12.42%

Boxlight Corporation, an education technology company, develops, sells, and services interactive classroom solutions for the education market worldwide. The company provides a range of interactive classroom technology products primarily targeted at the K-12 education market. Its products include interactive projectors, interactive flat panel displays, interactive touch projectors, touchboards, and MimioTeach that could turn any whiteboard interactive; and accessory document cameras, teacher pads for remote control, and assessment systems. The company also offers MimioStudio Interactive Instructional Software that enables the creation, editing, and presentation of interactive instructional lessons and activities; MimioMobile, a software accessory for MimioStudio; Oktopus Instructional and Whiteboarding Software that enables the creation, editing, and presentation of interactive instructional lessons and activities; Notes+, a software accessory for use with Oktopus software; and GameZones and MimioInteract, which are multi-student interactive gaming software. In addition, it offers interactive touch tables and whiteboards; and peripherals and accessories, such as amplified speaker systems, mobile carts, installation accessories, and wall-mount accessories for interactive and standard projectors, and LED flat panels. Further, the company distributes interactive projectors and LED flat panels; and science, technology, engineering, and math data logging and robotics products. It has a strategic partnership with CareHawk for providing audio solutions for the education market. The company was formerly known as Logical Choice Corporation. Boxlight Corporation was incorporated in 2014 and is headquartered in Lawrenceville, Georgia.

NASDAQ ended the session with Boxlight Corporation sliding 12.42% to $0.39 on Tuesday while NASDAQ rose 1.58% to $11,860.11.

Earnings Per Share

As for profitability, Boxlight Corporation has a trailing twelve months EPS of $-0.06.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.61%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Boxlight Corporation’s EBITDA is 14.3.

Sales Growth

Boxlight Corporation’s sales growth is negative 10.7% for the present quarter and 2.9% for the next.

Yearly Top and Bottom Value

Boxlight Corporation’s stock is valued at $0.39 at 17:32 EST, way under its 52-week high of $1.36 and way above its 52-week low of $0.26.

More news about Boxlight Corporation.

Stay up to date with our winners and losers daily report